| 產(chǎn)品編號 | bsm-52672R |
| 英文名稱 | RUNX2 Recombinant Rabbit mAb |
| 中文名稱 | 核心結(jié)合因子α1重組兔單抗 |
| 別 名 | Runx-2; RUNX2_HUMAN; Runt-related Transcription Factor 2; CBF alpha 1; CBF-alpha-1; PEBP2-alpha A; CBFA1; CCD; CCD1; Cleidocranial dysplasia 1; Core binding factor; Core binding factor runt domain alpha subunit 1; Core binding factor subunit alpha 1; MGC120023; Oncogene AML 3; OSF 2; OSF2; OSF-2; Osteoblast specific transcription factor 2; OTTHUMP00000016533; PEA2 alpha A; PEA2aA; PEBP2 alpha A; PEBP2A1; PEBP2A2; PEBP2aA1; Polyomavirus enhancer binding protein 2 alpha A subunit; Runt domain; Runt related transcription factor 2; SL3 3 enhancer factor 1 alpha A subunit; SL3/AKV core binding factor alpha A subunit; AML3; CLCD. |
| 研究領(lǐng)域 | 干細胞 轉(zhuǎn)錄調(diào)節(jié)因子 表觀遺傳學 |
| 抗體來源 | Rabbit |
| 克隆類型 | Recombinant |
| 克 隆 號 | 8H9 |
| 交叉反應 | Human,Mouse,Rat |
| 產(chǎn)品應用 | WB=1:500-2000,Flow-Cyt=1:50-100,ICC/IF=1:50-200
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 57 kDa |
| 檢測分子量 | |
| 細胞定位 | 細胞核 |
| 性 狀 | Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | A synthesized peptide derived from human RUNX2: 300-450/521 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 緩 沖 液 | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| 保存條件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| 注意事項 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產(chǎn)品介紹 |
This gene is a member of the RUNX family of transcription factors and encodes a nuclear protein with an Runt DNA-binding domain. This protein is essential for osteoblastic differentiation and skeletal morphogenesis and acts as a scaffold for nucleic acids and regulatory factors involved in skeletal gene expression. The protein can bind DNA both as a monomer or, with more affinity, as a subunit of a heterodimeric complex. Mutations in this gene have been associated with the bone development disorder cleidocranial dysplasia (CCD). Transcript variants that encode different protein isoforms result from the use of alternate promoters as well as alternate splicing. [provided by RefSeq, Jul 2008]. Function: Transcription factor involved in osteoblastic differentiation and skeletal morphogenesis. Essential for the maturation of osteoblasts and both intramembranous and endochondral ossification. CBF binds to the core site, 5'-PYGPYGGT-3', of a number of enhancers and promoters, including murine leukemia virus, polyomavirus enhancer, T-cell receptor enhancers, osteocalcin, osteopontin, bone sialoprotein, alpha 1(I) collagen, LCK, IL-3 and GM-CSF promoters (By similarity). Inhibits MYST4-dependent transcriptional activation. [SUBUNIT] Interaction with SATB2 results in enhanced DNA binding and transactivation by these transcription factors (By similarity). Heterodimer of an alpha and a beta subunit. Interacts with HIVEP3 (By similarity). The alpha subunit binds DNA as a monomer and through the Runt domain. DNA-binding is increased by heterodimerization. Interacts with XRCC6 (Ku70) and XRCC5 (Ku80). Interacts with MYST3 and MYST4. Subunit: Heterodimer of an alpha and a beta subunit. Interacts with HIVEP3. The alpha subunit binds DNA as a monomer and through the Runt domain. DNA-binding is increased by heterodimerization. Interacts with G22P1 (Ku70) and XRCC5 (Ku80). Interacts with MYST3 and MYST4. Subcellular Location: Nucleus. Tissue Specificity: Specifically expressed in osteoblasts. Post-translational modifications: Phosphorylated; probably by MAP kinases (MAPK). Isoform 3 is phosphorylated on Ser340. DISEASE: Defects in RUNX2 are the cause of cleidocranial dysplasia (CLCD) [MIM:119600]; also known as cleidocranial dysostosis (CCD). CLCD is an autosomal dominant skeletal disorder with high penetrance and variable expressivity. It is due to defective endochondral and intramembranous bone formation. Typical features include hypoplasia/aplasia of clavicles, patent fontanelles, wormian bones (additional cranial plates caused by abnormal ossification of the calvaria), supernumerary teeth, short stature, and other skeletal changes. In some cases defects in RUNX2 are exclusively associated with dental anomalies. Similarity: Contains 1 Runt domain. SWISS: Q13950 Gene ID: 860 Database links: Entrez Gene: 860 Human Entrez Gene: 12393 Mouse Omim: 600211 Human SwissProt: Q13950 Human SwissProt: Q9XSB7 Horse SwissProt: Q08775 Mouse Unigene: 535845 Human Unigene: 391013 Mouse Unigene: 391017 Mouse Unigene: 214214 Rat Unigene: 83672 Rat RUNX2又稱：Cbfα1(Core-binding factor, alpha 3 subunit) 是新發(fā)現(xiàn)的一類調(diào)控間充質(zhì)干細胞向成骨方向分化的特異性轉(zhuǎn)錄因子,參與骨形成,骨骼生長和發(fā)育的一類重要細胞,它起源于多能間充質(zhì)干細胞,是間充質(zhì)干細胞在體內(nèi)的各種調(diào)控因素的調(diào)節(jié)下發(fā)育而成的。 |
| 產(chǎn)品圖片 |
25 ug total protein per lane of various lysates (see on figure) probed with RUNX2 monoclonal antibody, unconjugated (bsm-52672R) at 1:1000 dilution and 4°C overnight incubation. Followed by conjugated secondary antibody incubation at r.t. for 60 min.
4% Paraformaldehyde-fixed PC-3 (H) cell; Triton X-100 at r.t. for 20 min; Antibody incubation with (RUNX2) monoclonal Antibody, unconjugated (bsm-52672R) 1:100, 90 min at 37°C; followed by conjugated Goat Anti-Rabbit IgG antibody (green, bs-60295G-BF488) at 37°C for 90 min, DAPI (blue, C02-04002) was used to stain the cell nuclei. PBS instead of the primary antibody was used as the blank control.
The PC-3 (H) cells were fixed with 4% PFA (10 min at r.t.) and then permeabilized with 90% ice-cold methanol for 20 min at -20℃,the cells then were incubated in 5%BSA to block non-specific protein-protein interactions (30 min at r.t.).Primary Antibody (green):Rabbit Anti-RUNX2 antibody (bsm-52672R,1:100); Secondary Antibody (white blue): Goat anti-Rabbit IgG-BF488(bs-60295G-BF488): 1 μg/test.Blank control (black): PBS. Acquisition of 20,000 events was performed.
|
| 1、抗體溶解方法 | |
| 2、抗體修復方式 | |
| 3、常用試劑的配制 | |
| 4、免疫組化操作步驟 | |
| 5、免疫組化問題解答 | |
| 6、Western Blotting 操作步驟 | |
| 7、Western Blotting 問題解答 | |
| 8、關(guān)于肽鏈的設(shè)計 | |
| 9、多肽的溶解與保存 | |
| 10、酶標抗體效價測定程序 | |
